In high-risk patients, the ideal cardiovascular gene therapy requires a strategy that provides long-term protection of myocardium against episodes of ischemic/reperfusion injury. We report the development of an efficient, long-lasting preemptive gene therapy strategy in a rat model of ischemicreperfusion (I/R) injury of heart. At 6 weeks prior to myocardial injury, the human extracellular superoxide dismutase (Ec-SOD) gene was delivered by direct intramyocardial injections, using a recombinant adeno-associated virus vector. Significant myocardial protection was documented by the decrease in infarct size at 24 h post I/R, improved left ventricular function at 7 weeks postinjury, and enhanced long-term survival in the SOD treated group. This concept of preinjury delivery and 'pre-emptive' gene therapy via the expression of a secreted protein that renders paracrine therapeutic action can be an effective strategy for organ protection against future injury.
Introduction
Patients with coronary artery disease are subject to episodes of overt or silent myocardial ischemia, alone or with reperfusion. This repeated myocardial injury can result in ischemic heart disease (IHD) leading to cardiomyopathy and heart failure. Pathophysiology of IHD involves myocardial damage induced by ischemia and/or oxidative stress due to reactive oxygen species (ROS) such as superoxide anion, hydroxyl radical and peroxynitrite. [1] [2] [3] Cellular defense against free radicals include antioxidant enzymes such as superoxide dismutase (SOD) and catalase. 4 A number of recent clinical studies have reported reduced levels of human extracellular superoxide dismutase (Ec-SOD) in patients with coronary artery disease and myocardial infarction. [5] [6] [7] Superoxide anion is product of oxygen metabolism and is produced by activated inflammatory cells. [8] [9] [10] SODs are family of metalloproteins that scavenges superoxide anion radicals and form oxygen and hydrogen peroxide. SOD acts indirectly to modulate NO availability, by attenuating superoxide anion mediated inactivation of NO. [11] [12] [13] Four isoforms of SOD exist based on metal cofactors and their localization. The copper-zinc (Cu/Zn)-SOD localized in cytoplasm of the eukaryotes, the manganese (Mn)-SOD present in mitochondria of aerobes, the iron (Fe)-SOD present in prokaryotes and the Ec-SOD found in the extracellular matrix and blood vessels of mammals. [14] [15] [16] [17] [18] Ec-SOD is an excellent candidate for gene therapy of ischemia/reperfusion (I/R) injury because it is secreted and acts on the extracellular matrix enabling a broader paracrine effect. [19] [20] [21] Protective role of Ec-SOD in scavenging ROS and reducing oxidative stressrelated I/R injury has been established in transgenic and knockout animal models. [22] [23] [24] [25] However, the therapeutic effect of recombinant Ec-SOD protein has been limited due to its low tissue availability and limited half-life of the protein. Therefore, a pre-emptive therapeutic strategy aimed at increasing levels of SOD using a viral vector that provides stable, long-term gene expression in IHD is desirable for protection against I/R injury.
Adeno-associated virus vectors show great potential as these viral vectors can infect nondividing cell, have low immune reactivity and ability to enable transgene expression for considerable length of time. [26] [27] [28] Moreover, these virus vectors can be made at very high titers and with different serotypes. 29, 30 Added to this is the advantage that vectors made from this parvovirus group do not exhibit pathogenicity in humans. We have previously reported that recombinant adeno-associated virus (rAAV) is effective for direct myocardial gene transfer. 31 Along with the ability for long-term expression of antioxidant enzyme in vivo, one can administer the therapeutic gene months in advance of the injury for future myocardial protection, thereby providing an effective approach to preventive therapy. Thus, the goal of this in vivo SOD study was to use rAAV, obtain efficient Ec-SOD gene expression and assess following acute I/R injury, the survival and long-term pre-emptive protection of the myocardium.
Results

AAV-LacZ vectors efficiency of transduction and gene expression
A pilot study was performed to assess quantity of virus vector that would give maximum transduction to potential 'area at risk'. Animals were injected and analyzed at 3, 6 and 12 weeks post transduction for expression of b-galactosidase staining. Gross analysis indicated transduction of 40-60% apex and 20-40% of mid-section of the heart. We found that minimum of 5 Â 10 10 particles of LacZ virus vector delivered by five direct injections of 150 ml each provided optimal transduction ( Figure 1 
SOD gene expression analyses in transduced rat hearts
Particles (5 Â 10 10 ) of either rAAV-LacZ or rAAV-Ec-SOD were directly injected into the free wall of rat ventricle.
Rats were analyzed at 6-8 weeks post transduction for expression of human Ec-SOD by RT-PCR. Presence of human Ec-SOD transcript was observed in the treated hearts by RT-PCR (Figure 2a ). Immunohistochemical analysis of transduced rat heart (Figure 2b) showed the presence of human Ec-SOD protein by specific antibody (a gift from Dr James Crapo, National Jewish Medical Center, CO, USA). At 6 weeks post transduction, presence of functional SOD protein in the Ec-SOD treated hearts was confirmed by a chemiluminescence's assay (Figure 2c ). This assay (Calbiochem, San Diego, CA, USA) measures ability of superoxide anion to oxidize luminol. Thus, low level of oxidized luminol reflects high levels of SOD activity. As compared to LacZ treated heart extracts, lower levels of oxidized luminol are observed in Ec-SOD transduced samples. These results indicate presence of functional SOD in the Ec-SOD transduced heart (Figure 2c ).
Acute I/R injury analyses by infarct size using triphenyltetrazolium (TTC) staining Recombinant adeno-associated virus gene therapy in heart RS Agrawal et al descending artery for 30 min. At 24 h post-reperfusion, Ec-SOD and LacZ treated animals were analyzed for infarct size based on TTC staining of the rat myocardium (Figure 3a ). Morphometric analysis of stained hearts was performed: the 'area at risk' and the 'infarct area' of the transduced hearts were measured. There was no significant difference in the 'area at risk' of the Ec-SOD compared to the LacZ treated hearts (Figure 3b ). However, there was a significant difference in size of infarct areas in the two groups. The SOD treatment with 2.5 Â 10 12 particles resulted in significant reduction in relative 'infarct size' compared to LacZ treatment ( Figure  3c ) and corresponded to about 79% relative protection of the myocardium (Figure 3d 
Acute I/R injury response of leukocytes
The transduce hearts were examined by histopathological analysis for assessment of acute injury after I/R. Immunohistochemical staining for rat CD45 antigen was performed in LacZ and Ec-SOD treated animals at 24 h post-injury to the myocardium (Figure 3e) . A large number of CD45 positive cells are seen in LacZ treated animals indicating a massive infiltration of leukocytes into the injury site but this was significantly reduced in Ec-SOD treated hearts ( Figure 3 ). This protection by human Ec-SOD has also been previously documented in a model of hyperoxic lung injury using transgenic animals. 21 
Assessment of the transduced rat hearts by echocardiography
In small animal models of cardiac injury, echocardiograph analyses have been shown to be a quick, reliable and sensitive measurement for assessment of global heart function. 32,33. Measurements were carried out before, and at 1, 7 and 49 days post I/R injury. Echocardiography performed at baseline before I/R showed no significant difference in % fractional shortening (FS) of SOD treated (N ¼ 19) versus the LacZ group (N ¼ 20). There were significant improvements in % FS at day 7 (N ¼ 19, P ¼ 0.009) and day 49 (N ¼ 12, P ¼ 0.0058) post I/R injury of the SOD treated animals. A 55% relative improvement in contractile function compared to LacZ treated animals was seen at day 49 ( Figure 4a ) postinjury. The relative diastolic dimension (ESD) in LacZ treated group steadily increased with time and were significantly different from treated SOD group at both 7 (P ¼ 0.02) and 49 (P ¼ 0.012) days post I/R event (Figure 4b ). There was no significant difference in the relative end-systolic dimension (EDD) for up to 7 days post-injury but this became significantly different at 49 days post (P ¼ 0.03) induction of injury (Figure 4c ).
Survival of the transduced rats based on Kaplan-Meier analysis
Following I/R injury, animals were randomized to either treatment modality for the survival study (Figure 5a ). There was significant improvement in survival (Pp0.002, students t-test, unpaired two-tail analysis) in Ec-SOD treated as compared to untreated LacZ group indicating that the presence of SOD protects myocardium during injury and results in better long-term survival of the Recombinant adeno-associated virus gene therapy in heart RS Agrawal et al animal. It is interesting to note that in this survival study in which we also performed serial echocardiography, we observed a significant difference (P ¼ 0.01) in mean % FS of the SOD (N ¼ 13) versus the LacZ (N ¼ 15, one animal died before day 1 echocardiograph, post-injury) treated animals at 1 day post I/R. When Kaplan-Meier curve was plotted according to % FS at day 1 post I/R, we found a significant influence of % FS on the surviving animals ( Figure 5b ), suggesting that myocardial functional salvage is an important determinant of survival and that % FS at 1 day postacute I/R injury may be a useful early predictor of survival.
Long-term functional SOD protein expression analyses in transduced hearts
Protein extract (5 mg obtained from left ventricle (LV) of rat hearts that were previously transduced with either LacZ or Ec-SOD was analyzed twice and in duplicates for functional Ec-SOD activity at 2 and 16 months after gene transfer ( Figure 6 ). Results show that in comparison to the LacZ transduced, and the right ventricle (RV) controls, there is persistent increase of functional SOD in the Ec-SOD treated ventricle (Figure 6a and b) . These results suggest that there is a long-term expression of functional protein in the myocardium of transduced rat hearts and could contribute to long-term protection and survival. Recombinant adeno-associated virus gene therapy in heart RS Agrawal et al
Discussion
We describe myocardial functional improvement and augmented animal survival against acute I/R injury of the rat heart by an in vivo AAV mediated 'pre-emptive' gene therapy. Our data showed that rAAV delivery of therapeutic gene Ec-SOD, 6-8 weeks prior to injury conferred long-term protection against future myocardial injury as assessed by the significant decrease in infarct size at 24 h postinjury and a significant improvement in left ventricular function at 7 weeks post I/R injury in the SOD treated animals. The infarct size was significantly reduced by 79% in the Ec-SOD (2.5 Â 10e 12 particles)-treated animals as opposed to the LacZ animals. At 7 weeks post I/R injury, this resulted in 55% relative improvement in FS as compared to the control group. Impressively, long-term survival was significantly improved in SOD treated group as compared to control LacZ treated group. Sustained increase of SOD was detected in the myocardium of SOD treated animals even at 16 months after gene transfer.
Our current study has three novel aspects: (1) the concept of pre-emptive gene therapy for myocardial protection, (2) the effectiveness of recombinant AAV vectors for in vivo delivery and long-term transgene expression, (3) the use of Ec-SOD as therapeutic transgene in a small animal model for I/R injury. The use of AAV vectors for gene therapy of the heart is particularly suitable as it is known to efficiently transduce muscle cell, it confers persistent long-term gene expression, and is associated with very low immunogenic response. In previous report, at least 30 min of continuous perfusion of the heart preparation ex vivo was necessary to obtain reasonable myocardial transduction. 34 Our study shows that localized gene delivery of AAV vectors using multiple direct injections can be used as an efficient delivery method for the expression of therapeutic levels of protein in the relevant cell type. This approach is more effective as our preliminary experiments also showed that intracoronary infusion of AAV-LacZ in vivo resulted in low transduction of the myocardium (data not shown).
We chose human Ec-SOD as the therapeutic gene because recent studies have shown that Ec-SOD is the major antioxidant enzyme of the vessel wall that is strategically located between the endothelium and the vascular smooth muscle cells. 18, 35 Vascular Ec-SOD activity correlated with the endothelium dependent vasodilatation and is low in patients with a history of myocardial infarction and coronary artery disease. 6 Restoration of Ec-SOD availability is associated with improvement of endothelial function in patients with CAD and is related to reduction of oxidative stress in vessel wall. 5 Earlier studies carried out in rats have shown that infusion of recombinant Ec-SOD protein resulted in reduced levels of creatine kinase in the left ventricular free wall and SOD bound to endothelial surface was also associated with lower cardiac damage in Langendorffperfused rat hearts subject to 15 min of global ischemia followed by reperfusion. 36 Subsequent comparative study conducted on infusion of recombinant Ec-SOD protein, Ec-SOD plus catalase and catalase alone showed inverse relationship between infarct size and creatine kinase levels in a pig myocardium injury model. 37 We selected gene therapy approach to increase availability and duration of Ec-SOD to the injured cardiomyocytes and showed that overexpression of Ec-SOD functionally protects myocardium in a small animal model of I/R injury. Endogenous peroxynitrites or H 2 O 2 could theoretically react with luminol used for the functional assessment of the SOD activity in this study; however, it is unlikely since SOD itself inhibits formation of new peroxynitrite and the assay was performed at pH 7.6, and compared to the I/R rAAV-LacZ treated controls. Several previous studies have examined acute I/R after coronary occlusion by using SOD and/or catalase gene therapy to reduce damage to heart. Work done by Li et al 38 in conscious rabbit model reported that Ec-SOD gene transfer with short-term gene expression protected the myocardium against acute infarction. This study used systemic delivery of adeno-virus vector to obtain immediate short-term effect, and differ from our approach of using AAV vector for long-term action. Indeed, none of the studies to date have examined the long-term preventive effect of Ec-SOD expression in vivo on late myocardial I/R injury with follow-up of cardiac function and survival as the end points.
Our results not only show reduction in infarct size with long-term improvement in cardiac function but we also report an improved survival of the SOD treated animals after I/R injury. The improved survival of the SOD treated rats is primarily due to protection against initial ischemic injury, as no subsequent injuries were attempted in the current study. The difference in survival between SOD versus LacZ treated rats cannot be due to deleterious effect of LacZ expression since our previous work has shown no significant difference in infarct sizes of the saline versus the LacZ treated animals. 31 In vivo studies on aging and I/R in rats have shown to have no effect on mitochondrial, cytosolic or total SOD activity. Myocardium is a rich source of mitochondrial DNA and consequently a significant source of ROS during I/R. Our current long-term study of Ec-SOD gene therapy, using a single I/R episode in a small animal model, further strengths its role in protection against myocardial injury. Effect of long-term Ec-SOD expression on survival is intriguing and requires further investigation, especially since SOD may have a beneficial role in the aging process via its antioxidant effect.
Finally, the delivery of therapeutic gene in our study was performed 6-8 weeks prior to myocardial injury. Our results demonstrated the expression of Ec-SOD and the therapeutic action of its product many months after gene transfer. This approach introduces the concept of pre-emptive gene therapy for myocardial protection. Since in the presence of coronary artery disease, myocardium maybe subject to repeated episodes of ischemia and possibly reperfusion injury, the preexistence of a cardioprotective transgene may attenuate the consequences of these episodes. Indeed, we show evidence for expression of functional SOD, 16 months after gene delivery using AAV vector. We propose that in the future, pre-emptive myocardial gene therapy may have initial utility in selected high-risk patients undergoing interventional or surgical revascularization procedures. These may include patients who are at an increased risk for coronary events such as those with multivessel disease, diabetes and multiple risk factors and/or prior myocardial infarction.
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Materials and methods
Adeno-associated virus vector construct
Human Ec-SOD cDNA was a generous gift from Professor Stefan Marklund (University of Umeä, Sweden). A 1396-bp EcoRI fragment bearing the cDNA for human Ec-SOD from plasmid pPS3 was cloned between the inverted terminal repeats of rAAV vector containing the cytomegalovirus promoter and bovine growth hormone polyadenylation sequence (Figure 1a) . The design of the rAAV LacZ vector was similar except that the cDNA was replaced with b-galactosidase gene (Figure 1a ). Prior to large-scale production of rAAV vectors, all vectors used in the current study were sequenced, and tested in vitro on human HEK 293 cell line. Transfected human HEK293 cells were assessed for presence of Ec-SOD by Western blots and expression of functional SOD protein by biochemical analysis.
RT-PCR
Total RNA (1 mg) was analyzed by one-step RT-PCR kit (Invitrogen, Carlsbad, CA, USA) for presence of SOD transcript in rat hearts transduced with either Ec-SOD or LacZ vector. RT and PCR negative controls were used to determine the specificity of the experiment. Ec-SOD specific PCR product was amplified using forward: GGAGCCCAACTCTGACT, reverse: TTCTCCACGCTG GCCT primers.
Vector production
Virus vectors were made as previously described, 39 at the Harvard Gene Therapy Initiative, vector production core using standard operating procedures. In all, 5 Â 10 10 total virus vector particles per animal were used for the study unless otherwise stated. All rats were transduced by five direct injections of 150 ml each, to free wall of the left ventricle adjacent to the area of I/R injury. The use of virus for both in vitro and in vivo studies was approved through the institutional committee of microbiology safety.
Animal surgery and transductions
All surgical procedures were approved by Harvard Medical Area standing committee on animals, and performed according to institutional guideline. Male Harlan Sprague-Dawley rats (200-250 g body weight) were anesthetized by an intraperitoneal injection of ketamine (70 mg/kg) and xylaxine (4 mg/kg). Animals were intubated via a tracheotomy and ventilated with Harvard rodent respirator (Harvard, S Natick, MA, USA). The chest was opened by a small incision, and virus vector was directly injected to five points in the free wall of left ventricle. For all experiments, a 32-gauge needle (Roboz Surgical Instrument Company, Rockville, MD, USA) was used to deliver the virus vector to the myocardium. Animals received five injections of 150 ml each of either rAAV-LacZ control or rAAV-Ec-SOD virus vector treatment targeted to the potential 'area at risk' for I/R injury. Potential 'area at risk' after acute I/R injury was estimated by Evans blue exclusion as previously described. 31 The 5-0 Ticron blue polyester sutures were used to close the chest wall. The respirator and the endotracheal tube were then removed and animal was allowed to recover under a warm heat lamp. The animals were then housed for a period of 6-8 weeks before induction of an acute I/R injury.
Functional SOD expression
In total, 50 mg (in tubes) or 5 mg (in microtiter plates) of protein extract from rat hearts that were previously transduced with either Ec-SOD or LacZ were used to measure ability of superoxide anion to oxidize luminol. The chemiluminescence's (Calbiochem, San Diego, CA, USA) assay was performed according to the manufacturer's instructions. In the assay, enzyme kinetics is measured with time and low levels of oxidized luminol reflect high level of SOD activity in the samples. Right ventricle (RV) of SOD, or LacZ transduced rat heart was used as a negative control and pure SOD enzyme as positive control.
Development of acute I/R injury model and TTC staining for the hearts At 6 weeks after gene transfer, I/R injury was induced in rats as previously described. 31-33. Briefly, using a 6-0 silk suture, Left Anterior Descending (LAD) artery was ligated at 3-4 mm from its point of origin. The ligature was tightened and the vessel was occluded for 30 min. Thus, acute ischemic injury was induced and confirmed in all rats by presence of discoloration of ischemic area and change in cardiac rhythm. Animals were then reperfused for 4, 8 and 24 h and analyzed for levels of glutathione, SOD and total lipid peroxides. Based on decrease in glutathione and SOD levels and increase in total lipid peroxides (data not shown), 24 h postreperfusion time was chosen for assessment of myocardial damage. Reperfusion was confirmed by resumption of normal rhythm and color to ischemic area. In gene delivery experiments, all five injections of the virus vectors were targeted to the potential 'area at risk'. There was no death during the first surgery, when virus vector was delivered to the rat myocardium. During the second surgery, 4/54 animals died at the time of I/R injury.
Infarct size and TTC staining
Ischemic 'area at risk' and infarct size in each animal were measured as previously described. 31 . Briefly, after 24 h of reperfusion, LAD was religated and 1% Evans blue was injected into the heart to determine potential 'area at risk' based on dye exclusion. Heart was then immediately excised, rinsed of excess dye, sliced transversely into 2-mm-thick sections. They were stained in 1% TTC at 371C until the viable myocardium stained brick red. Sections were then fixed in 5% formalin for 24 h and photographed by an Olympus OM-2 camera containing 90-mm macrolens and 2 Â teleconverter. The slides were projected at approximately Â 10 magnification and traced on a graph paper. On each slide, potential 'area at risk' was calculated and is area of left ventricle that excluded the Evans blue dye upon ligation of LAD. The 'infarcted area' is an area that remained unstained or pale yellow upon TTC staining. All measurements are in relative units. Relative 'infarct size' was measured as ratio of 'infarcted area' to potential 'area at risk' and is represented as '% infarct size'. Cumulative area of all sections of each heart was calculated and statistical significance of mean7s.e. of the treated versus untreated Recombinant adeno-associated virus gene therapy in heart RS Agrawal et al group was determined using an unpaired, two-tailed Student's t-test.
Echocardiography
Serial echocardiograms data was obtained in anesthetized rats before and after 1, 7 and 49 days of I/R injury to the transduced rat hearts. Short axis echocardiography images were obtained by Sonos 5500 (Agilent Technologies, Palo Alto, CA, USA) workstation and 12-MHz transducer. Left ventricular end-diastolic (EDD) and endsystolic dimension (ESD) measurements were manually digitized, using parasternal short axis view 33 and were in millimeter units. Percentage FS was calculated as % FS ¼ (EDD-ESD)/ (EDD) Â 100. Three consecutive cardiac cycles were averaged for each measurement. Each rat heart measurement was conducted in triplicate under light ether anesthesia and spontaneous respiration. Throughout the study, investigator performing the echocardiography measurements was blinded to the mode of treatment.
Statistical analysis
Data is represented as mean7s.e. and comparison between Ec-SOD versus LacZ treated samples was carried out using an unpaired, two-tailed Student's t-test. For all analyses, P values p0.1 was considered as significant.
